

Nycomed Amersham plc

[View the current Nycomed Amersham plc Page on BioPortfolio.com](http://www.bioportfolio.com/bi corporate/7739-Nycomed+Amersham+plc.html)

(<http://www.bioportfolio.com/bi corporate/7739-Nycomed+Amersham+plc.html>)

Contact Details:

Amersham Place

Tel: +44 (0) 1494-544000

Fax: +44 (0) 1494-542266

Email:

Little Chalfont

Buckinghamshire

HP7 9NA

United Kingdom

Amersham plc is a world leader in medical diagnostics and in life sciences, delivering pharmaceutical products for the diagnosis and treatment of disease and technologies for biotechnology research and drug discovery. Headquartered in the UK, the company has annual sales of £1.4 billion (US\$ 2.1 billion) and 9,000 employees worldwide.

Recent Publications by Nycomed Amersham plc:



- [Effects of topiramate on kainate- and domoate-activated \[14C\]guanidinium ion flux through GluR6 channels in transfected BHK cells using Cytostar-T scintillating microplates.](#)
*PURPOSE: This study was undertaken to test the hypothesis that topiramate...*29th April, 2000
Nycomed Amersham plc, Cardiff, United Kingdom.- *Epilepsia*. 2000;41 Suppl 1:S48-51.
- [Biologic mechanisms of 89SrCl2 incorporation into type I collagen during bone mineralization.](#)
*89SrCl2 is currently used as a palliative treatment for painful osseous...*26th February, 2000
Nycomed Amersham plc, Imaging Research and Development, Amersham- *J Nucl Med*. 2000 Jan;41(1):183-8.

Press Releases on Nycomed Amersham plc:

["As an Industry, We've Been too Focused on Regulatory Approval." Says Solvay Pharmaceuticals Eric Rambeaux at the Pharma Marketing Summit.](#)

26th November, 2009

LONDON, November 26 /PRNewswire/ -- Rambeaux joined a host of other industry leaders at eyeforpharma's 9th annual Pharma Marketing Summit 2009 conference in Berlin, where several key themes

[SSL International plc Embraces TrackWise\(R\) Software for Global Quality and Compliance Efforts](#)

24th November, 2009 Sparta Systems, Inc.

HOLMDEL, N.J., Nov. 24 /PRNewswire/ -- Sparta Systems, Inc., the maker of TrackWise software and the market leader in enterprise quality and compliance solutions, today announced that SSL

[Aflac To Exchange Two Lloyds Banking Group Securities, Enhance Risk-Based Capital Ratio](#)

24th November, 2009 Aflac Incorporated

COLUMBUS, Ga., Nov. 24 /PRNewswire-FirstCall/ -- Aflac Incorporated (NYSE: AFL) announced today that the Lloyds Banking Group plc has accepted the exchange of two of its investment securities owned by

[Shire Submits European Marketing Authorization Application \(MAA\) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease](#)

24th November, 2009

DUBLIN, November 24 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has submitted a MAA to the European Medicines Agency

[Victory Pharma, Inc. Announces Launch of NAPRELAN\(R\) Dose Card](#)

23rd November, 2009 Victory Pharma, Inc.

SAN DIEGO, Nov. 23 /PRNewswire/ -- Victory Pharma, Inc. ("Victory") announced today the launch of NAPRELAN® Dose Card, a further extension of Victory's NAPRELAN franchise. NAPRELAN

Nycomed Amersham plc Patents:



- 6653299- [Labelled factor XIIIa substrates](#)
- 5922301- [Radiolabelled amino acid formulations stored in an unfrozen state](#)
- 5932707- [Thioether-containing metal chelating compounds](#)
- 6001979- [Cores for technetium radiopharmaceuticals](#)
- 6004531- [Metal chelating compounds having an SNNN donor set](#)
- 6124440- [Cores for technetium radiopharmaceuticals](#)
- 6132359- [Brachytherapy seeds](#)
- 6132698- [Radiolabelled compound formulations containing a dye](#)
- 6153775- [Polydentate imines and their metal complexes](#)
- 6329513- [Cores for technetium radiopharmaceuticals](#)
- 6348599- [Cyanine dyes](#)
- 6360183- [Device and method for triggering a random event](#)
- 6444682- [Base analogues](#)
- 6458966- [Dye intermediate and method](#)
- 6605611- [Base analogues](#)
- 5874811- [Superconducting cyclotron for use in the production of heavy isotopes](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road,
Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

